<DOC>
	<DOCNO>NCT01277705</DOCNO>
	<brief_summary>This study assess immunogenicity reactogenicity candidate GSK Biologicals ' reduce antigen diphtheria tetanus toxoid acellular pertussis- inactivated poliovirus vaccine administer healthy subject age ≥ 15 year Germany ≥ 18 year France compare Boostrix™ inactivate poliovirus vaccine administer separately , Revaxis®</brief_summary>
	<brief_title>Comparison GSK Biologicals ' Reduced Antigen Diphtheria Tetanus Toxoids Acellular Pertussis- Inactivated Poliovirus Vaccine , BoostrixTM Inactivated Poliovirus Vaccine Administered Separately With Revaxis®</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female subject age 15 year ( Germany ) , 18 year ( France ) time vaccination . Written inform consent obtain . Free obvious health problem Having receive primary vaccination diphtheria tetanus vaccine best his/her knowledge . Female subject must pregnant lactating . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede administration study vaccine dose , plan use study period . History previous intercurrent diphtheria tetanus , pertussis polio disease last 10 year . French subject : history diphtheria tetanus , pertussis polio vaccination last 10 year . German subject : history diphtheria tetanus , pertussis polio vaccination last 5 year , except subject participate tetanus antibody kinetic subgroup . German subject participate tetanus antibody kinetic subgroup : history diphtheria tetanus , pertussis polio vaccination last 10 year . Administration plan administration vaccine foreseen study protocol period start 30 day administration study vaccine dose end 30 day study vaccination . Chronic administration plan administration immunosuppressant immunemodifying drug within six month 5 halflives ( whichever longer ) vaccination . Administration immunoglobulins and/or blood product within three month precede study vaccination plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , History seizures progressive neurological disease . Major congenital defect serious chronic illness . Acute disease time enrolment . History allergic disease reaction likely exacerbate component vaccine ( ) . The following adverse experience associate diphtheriatetanuspertussis vaccination constitute absolute contraindication administration diphtheriatetanuspertussis vaccine ; adverse experience occur follow previous vaccination , subject include : Absolute contraindication : Hypersensitivity reaction due vaccine . Encephalopathy Precautions : Fever &gt; = 40.0°C within 48 hour vaccination due another identifiable cause . Collapse shocklike state within 48 hour vaccination . Persistent , inconsolable cry last &gt; = 3 hour occur within 48 hour vaccination . Seizures without fever occur within 3 day vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Booster vaccination</keyword>
</DOC>